Dashboard
1
Poor Management Efficiency with a low ROCE of 4.73%
- The company has been able to generate a Return on Capital Employed (avg) of 4.73% signifying low profitability per unit of total capital (equity and debt)
2
The company is Net-Debt Free
3
Poor long term growth as Net Sales has grown by an annual rate of 4.64% and Operating profit at -1.64% over the last 5 years
4
Positive results in Jun 26
5
With ROE of 4.97%, it has a fair valuation with a 3.28 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 10,492 Million (Mid Cap)
66.00
NA
0.23%
0.14
4.06%
3.58
Revenue and Profits:
Net Sales:
521 Million
(Quarterly Results - Jun 2026)
Net Profit:
33 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
8.23%
0%
8.23%
6 Months
44.93%
0%
44.93%
1 Year
77.9%
0%
77.9%
2 Years
303.08%
0%
303.08%
3 Years
140.6%
0%
140.6%
4 Years
71.26%
0%
71.26%
5 Years
56.58%
0%
56.58%
Ningbo Menovo Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
4.64%
EBIT Growth (5y)
-1.64%
EBIT to Interest (avg)
3.99
Debt to EBITDA (avg)
3.39
Net Debt to Equity (avg)
0.40
Sales to Capital Employed (avg)
0.37
Tax Ratio
25.16%
Dividend Payout Ratio
23.23%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
4.00%
ROE (avg)
7.75%
Valuation key factors
Factor
Value
P/E Ratio
66
Industry P/E
Price to Book Value
3.28
EV to EBIT
56.21
EV to EBITDA
33.51
EV to Capital Employed
2.69
EV to Sales
5.51
PEG Ratio
1.17
Dividend Yield
NA
ROCE (Latest)
4.79%
ROE (Latest)
4.97%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Bullish
Moving Averages
Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
521.20
337.70
54.34%
Operating Profit (PBDIT) excl Other Income
99.60
44.50
123.82%
Interest
0.00
10.70
-100.00%
Exceptional Items
-3.80
-3.70
-2.70%
Consolidate Net Profit
33.10
32.50
1.85%
Operating Profit Margin (Excl OI)
121.90%
131.80%
-0.99%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is 54.34% vs -12.58% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is 1.85% vs 550.00% in Mar 2026
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
1,498.90
1,368.30
9.54%
Operating Profit (PBDIT) excl Other Income
278.50
220.90
26.08%
Interest
44.40
49.10
-9.57%
Exceptional Items
4.00
24.30
-83.54%
Consolidate Net Profit
106.10
76.00
39.61%
Operating Profit Margin (Excl OI)
93.30%
61.50%
3.18%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 9.54% vs 12.65% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 39.61% vs 369.14% in Dec 2024
About Ningbo Menovo Pharmaceutical Co., Ltd. 
Ningbo Menovo Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






